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Randomized controlled trialObjective. The aim of this study was to assess the superiority of ICG-99mTc-nanocolloid for the intraoperative
visual detection of sentinel lymph nodes (SLNs) in vulvar squamous cell carcinoma (VSCC) patients compared to
standard SLN detection using 99mTc-nanocolloid with blue dye.
Methods. In this multicenter, randomized controlled trial, VSCC patients underwent either the standard SLN
procedure or with the hybrid tracer ICG-99mTc-nanocolloid. The primary endpoint was the percentage of fluores-
cent SLNs compared to blue SLNs. Secondary endpoints were successful SLN procedures, surgical outcomes and
postoperative complications.
Results. Forty-eight patients were randomized to the standard (n = 24) or fluorescence imaging group
(n = 24) using ICG-99mTc-nanocolloid. The percentage of blue SLNs was 65.3% compared to 92.5% fluorescent
SLNs (p < 0.001). A successful SLN procedure was obtained in 92.1% of the groins in the standard group and
97.2% of the groins in the fluorescence imaging group (p = 0.33). Groups did not differ in surgical outcome,
although more short-term postoperative complications were documented in the standard group (p = 0.041).
Conclusions. Intraoperative visual detection of SLNs in patients with VSCC using ICG-99mTc-nanocolloid was
superior compared to 99mTc-nanocolloid and blue dye. The rate of successful SLN procedures between both
groups was not significantly different. Fluorescence imaging has potential to be used routinely in the SLN proce-
dure in VSCC patients to facilitate the search by direct visualization.
Clinical Trial Registration: Netherlands Trial Register (Trial ID NL7443).
© 2020 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http://
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The sentinel lymph node (SLN) procedure has been proven to be a
reliable and safe method in patients with early-stage vulvar squamous
cell carcinoma (VSCC) [1–3]. For unifocal VSCCs, with a diameter of
4 cm or less and without suspected or enlarged groin lymph nodes,
the current standard treatment consists of a radical local excision of
the tumor and a SLN procedure, ipsilateral or bilateral depending on lo-
cation of the vulvar tumor and outcome of lymphoscintigraphy [1–5]. A
full inguinofemoral lymphadenectomy (IFL) is advised when the SLN is
not identified either by lymphoscintigraphy or during surgery. There-
fore, the SLN procedure should be optimal to guarantee safety andmin-
imize the need to perform a full IFL.
Standard SLN detection in vulvar cancer patients consists of a preop-
erative peritumoral injection with 99mTc-nanocolloid as a radiotracer,
preoperative lymphoscintigraphy and the intraoperative use of radio-
guidance and additional blue dye for visual imaging [2–5]. Meta-
analyses show that the overall SLN detection rate with the combined
use of 99mTc-nanocolloid and blue dye is 87–93% per groin [4,6] and
98% per patient [5,6]. Blue dye enables direct visualization of the SLN
and facilitates the detection of the SLN during surgery. However, only
63–69% of the SLNs were visualized intraoperatively with the use of
blue dye [4–6]. Hence, in more than 30% of the cases, the surgeon has
to rely solely on the guidance by the gamma probe to identify the SLN.
In such cases, localization of the SLN can be hampered when the back-
ground signal originating from the injection spot around the vulvar
tumor disturbs the signal of the SLN. Difficult identification of the SLN
may result in larger incisions, whichmight increase the risk of postoper-
ative complications, and prolonged timeof surgery.More importantly, if
the SLN cannot be identified, an IFL is recommended. This is associated
with increased acute and late morbidity such as wound dehiscence, in-
fection, lymphocele formation and lymphedema [2,7,8].
Furthermore, blue dye has the disadvantage that is not visible
through the skin or other overlying tissues, but only by direct visualiza-
tion. In addition, the injection of blue dye results in discolouring of the
vulva which may hamper proper sight of the surgical field and could
have a negative impact on achieving tumor-free resection margins.
Near-infrared (NIR) fluorescence imaging has emerged as a comple-
mentarymethod for intraoperative visualization of tumor tissue [9] and
SLNs [10–19]. By peritumoral injection of indocyanine green (ICG), a
FDA approved 800 nm fluorophore, in a complex with 99mTc-
nanocolloid (ICG-99mTc-nanocolloid), SLNs can be visualized in real-
time by using a NIR fluorescence imaging system. Indocyanine green
is invisible to the naked eye and does not colour the surgical field. Fur-
thermore, use of wavelengths in the NIR spectrum results in a penetra-
tion depth of approximately 5–8 mm. With ICG-99mTc-nanocolloid, the
SLN biopsy procedure became more accurate in patients with various673malignancies such as penile cancer, melanoma, and vulvar cancer, and
allowed for superior optical surgical guidance compared to blue dye
[11,12,14,15,17].
Several studies showed good feasibility of NIR fluorescence imaging
to identify SLNs in vulvar cancer patients using ICG separately and
99mTc-nanocolloid for radio-guidance [12,13,16,20] or hybrid
ICG-99mTc-nanocolloid [14,15,19]. Combining the results of these stud-
ies, 96.6% of all SLNswere visualized during surgery byNIR fluorescence
imaging compared to 70.6% of the SLNs by blue dye [21]. However, in
these studies the different techniques were combined with blue dye in
the same patient. Until now, the superiority of ICG-99mTc-nanocolloid
for the intraoperative visualization of the SLN compared to standard
SLNdetectionhasnotbeenstudied.Therefore, theaimof thiscurrentran-
domized controlled study was to assess the superiority of ICG-99mTc-
nanocolloid for the intraoperative visual detection of SLNs compared to
the standard SLN procedure using 99mTc-nanocolloid and blue dye.
2. Methods
This multicenter, randomized controlled superiority trial, was per-
formed at the Leiden University Medical Center (LUMC) in Leiden and
the Erasmus Medical Center in Rotterdam, The Netherlands. Fig. 1 pre-
sents a flow diagram of the study. The study was centrally approved
by the Medical Ethics Committee of the LUMC (CME Leiden P09.001)
and registered at the Netherlands Trial Register (Trial ID NL7443).
The primary outcome was defined as the percentage of intraopera-
tive visualized SLNs that were fluorescent compared to the percentage
of SLNs that coloured blue. Secondary outcomes included: rate of suc-
cessful SLN procedures per groin, percutaneous visualization of a lym-
phatic channel or SLN, length of incision, duration of SLN procedure,
intra- and postoperative complications, and pathological outcome.
2.1. Patients
Eligible patients (age ≥ 18 years) had primary VSCC (T1b, FIGO stag-
ing 2014), tumor size <4 cm diameter, a depth of invasion of >1 mm
and clinically and radiologically nonsuspicious inguinofemoral lymph
nodes. Exclusion criteria were multifocal tumors, groin operations that
might hamper SLN identification, and an allergy to iodine, patent blue,
shellfish or ICG. All patients provided written informed consent.
2.2. Tracer preparation
For the patients in the standard group 99mTc-nanocolloid was pre-
pared by the Department of Nuclear Medicine according to local proto-
col [19]. Tracer preparation was performed under Good Manufacturing
Fig. 1. Flow diagram of the study. SLN; sentinel node, IFL; inguinofemoral lymphadenectomy1 In two patients with a midline tumor (one group each), lymphoscintigraphy showed an
unilateral SLN and an elective, contralateral IFL was performed. 2 One patient in the standard group with a midline tumor and unilateral SLN identified on lymphoscinitgraphy,
underwent a bilateral IFL, despite a successful SLN procedure unilateral (i.e. protocol deviation).
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pharmacist. For patients in the fluorescence imaging group the tracer
ICG-99mTc-nanocolloid was commercially obtained from GE Healthcare
Radio pharmacy (Leiderdorp, The Netherlands), in collaboration with
the InterventionalMolecular Imaging Laboratory of the LUMC. For prep-
aration 25 mg ICG was dissolved in 5 ml sterile water. Fifty μl of this
freshly prepared ICG solution (5 mg/ml) was subsequently added to
2.000 MBq 99mTc-nanocolloid in 2 ml. From this vial a dose of
52–100MBq, calibrated at the time of injection, was extracted for injec-
tion of the hybrid tracer ICG-99mTc-nanocolloid. The ICG concentration
was approximately 161 μmol/l, leading to an injected ICG dose of
0.12 mg.
2.3. Study design and preoperative imaging
Consecutive patients with VSCC who fulfilled the inclusion criteria
and gave consent, were included between June 2016 and September
2019 (Fig. 1). Randomization with a computer-generated random
block size was used at a 1:1 ratio. No stratification was done. Patients674were assigned to either the standard group using 99mTc-nanocolloid
and blue dye or fluorescence imaging group using ICG-99mTc-
nanocolloid. Randomization and central data management was per-
formed at the LUMC. Included patients who were excluded before the
conduct of study procedures were replaced by consecutive patients.
For the standard SLN [2,3] and fluorescence imaging procedure, 4
peritumoral injections of a total of approximately 0.5 ml 52–100 MBq
of respectively 99mTc-nanocolloid or the hybrid tracer with ICG-99mTc-
nanocolloid, were administered 3–20 h before surgery. In patients in
whom the vulvar tumor was already excised, the tracer was intracuta-
neously injected around the excision scar.
Following administration of the radioactive tracer, an early and late
dynamic lymphoscintigraphy was performed (Symbia T6, Siemens, Er-
langen, Germany). The number and site of SLNs visualized on
lymphoscintigraphywere noted per groin [2,4]. In patients with tumors
crossing the midline, in whom a single sided SLN was identified, an IFL
was advised on the side in which the SLN was not identified. In case of
a lateral tumor, i.e. not crossing the midline, unilateral identification of
SLN on lymphoscintigraphy was appropriate.
Table 1




Number of patients 24 24
Age (years)
Median (range) 71 (44–88) 68 (51–90)
BMI in kg/m2 (± SD) 28.0 ± 5.2 28.2 ± 5.4
Location of primary tumor, n (%)
Lateral 15 (62.5%) 18 (75.0%)
Midline 9 (37.5%) 6 (25.0%)
Tumor diameter (mm)
Mean (range) 19.0 (8–40) 20.7 (10–40)
Tumor infiltration depth (mm)
Mean (range) 3.4 (1−10) 2.6 (1–7)
Hospital of surgery
Leiden University Medical
Centre, Leiden 16 (66.7%) 16 (66.7%)
Erasmus Medical Centre,
Rotterdam 8 (33.3%) 8 (33.3%)
Planned local treatment
Wide local excision and SLN
procedure
22 (91.7%) 19 (79.2%)
Re-excision and SLN procedure 1 (4.2%) 4 (16.7%)
Only SLN procedure (previously
excision of vulva tumor)
1 (4.2%) 1 (4.2%)
ICG; indocyanine green, BMI; Body Mass Index, SLN(s); sentinel lymph node(s).
* There were no significant differences between the trial groups in any of the variables
listed in this Table.
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A handheld gamma probe (EuroProbe 3.2, Eurorad, Eckbolsheim,
France) was used to identify the location of the SLN(s) for all proce-
dures. In the study group, fluorescence imaging was performed by the
Quest Spectrum Imaging System (QuestMedical Imaging, Middenmeer,
The Netherlands).
The SLN procedure was performed as described previously [1,2]. In
brief, in the standard group, prior to the first groin incision, 1–2 ml of
Patent Blue V (Guerbert, France) was injected intracutaneously at 4
peritumoral locations. For each groin the percutaneously identification
of a lymphatic channel or SLN with fluorescence imaging or blue dye
was determined before incision. The skin incision was made at the
point of the greatest radioactive signal and/or the site of percutaneous
fluorescence imaging signal. A SLN was defined as a (first) lymph
node that showed adequate concentration of tracer agent, i.e. radioac-
tive signal and/or a visible blue or fluorescent node [22]. For each
resected SLN, the radioactivity (total gamma count) and/or presence
of blue dye or fluorescence (in and/or ex vivo) was noted. After SLN ex-
cision, the wound bed was checked to assure no blue dye, fluorescence
or significant radioactive signal was left. In case the remaining radioac-
tive signal was >10% of the signal of the first or most radioactive SLN,
the dissection was continued to search for additional SLNs [1,4,6,22]. If
more radioactive and/or blue or fluorescent SLNswere resected as iden-
tifiedon lymphoscintigraphy in the respective groin, thesewere defined
as additional SLNs [14]. In case no SLN at all was identified in patients in
the fluorescence imaging group, a blue dye injection was advised to
offer the standard procedure. In all patients, an IFL was advised if no
SLN was detected.
A SLN procedure was defined as successful when at least one SLN
was detected during surgery, and remaining tissue showed less than
10% radioactivity compared to the most radioactive SLN [1,4].
The successful SLN procedure rate per groin was calculated as
the number of groins in which a SLN was detected, divided by the
number of groins in which a SLN should be identified and resected ac-
cording to tumor location and results of the lymphoscintigraphy [4].
Furthermore, a complete SLN procedure was defined as the intraopera-
tive detection and removal of all SLNs that were identified on
lymphoscintigraphy in the respective groin.
The length of groin incision, intraoperative blood loss and complica-
tions were listed. Duration of SLN procedure, defined by the time inter-
val between skin incision and final excision of all SLNs was noted. In
case of failed SLN detection, time interval between skin incision and
completion of IFL was noted.
2.5. Pathological examination
The resected specimen of the vulva and resected SLNs and other tis-
suewere examined by the pathologist according to standard protocol in
both hospitals. The SLNswere fixed in formalin and embedded in paraf-
fin for haematoxylin, eosin, and immunopathological staining for
cytokeratin AE1/AE3 at multiple levels (ultra-staging), with an interval
of 250 μm [2,3].
2.6. Postoperative complications
Short-term complications (<6 weeks after surgery) of the groin in-
cluded wound breakdown or infection requiring treatment, and/or
lymphocyst formation [7]. Long-term complications (>6 weeks after
surgery), such as lymphedema and recurrent erysipelas, requiring any
treatment were also registered [7].
2.7. Sample size and statistical analysis
The study has been powered using a two independent proportions
power analysis. The used outcome was the proportion of fluorescent675SLNs (96.6%) [21] compared to blue coloured SLNs (68.7%) [5]. To per-
ceive a significant difference between the amount of SLNs which are
blue and those that are fluorescent, a total of 48 patients should be in-
cluded (α = 0.05; β = 0.2). For statistical analysis, IBM SPSS Statistics
(Version 25, La Jolla, CA, USA) was used. For the secondary outcomes
an intention-to-treat analysis was performed. To evaluate the differ-
ences between the standard and fluorescence imaging groups t-test,




Fifty-two patients with vulvar cancer were assessed for eligibility
(Fig. 1). Four patients were excluded due to not meeting the inclusion
criteria (n = 2) or because ICG-99mTc-nanocolloid was not available at
that time (n = 2). After randomization 24 patients were allocated to
each group. Patient and tumor characteristics are shown in Table 1.
Baseline characteristics did not differ between both groups.
3.2. Preoperative SLN detection by lymfoscintigraphy
The schedules of peritumoral injections of the tracer are shown in
Table 2. Patients in the fluorescence imaging group received a signifi-
cantly higher radioactivity dose of 99mTc-nanocolloid compared to the
standard group (p < 0.001). In the standard group a total of 52 SLNs
were identified on lymphoscintigraphy in 37 groins, compared to 41
SLNs in 35 groins in the fluorescence imaging group (Table 2). In each
group, in one patient with a midline tumor, only an unilateral SLN was
identified on lymphoscintigraphy. Bilateral SLNs in lateral tumors
were identified in five (20.8%) patients in the standard group and in
six (25%) patients in the fluorescence imaging group (p = 0.745).
3.3. Intraoperative SLN detection
A total of 49 SLNs in 37 groins were resected in the standard group
compared to 53 SLNs in 35 groins in the fluorescence imaging group
Table 2
Preoperative identification of sentinel lymph nodes on lymphoscintigraphy.
Characteristics, n (%) 99mTc-nanocolloid + blue dye ICG-99mTc-nanocolloid P-value
Number of patients






4 × 13–15 MBq day of surgery 13 (54.2%) 9 (37.5%)
4 × 15 MBq day before surgery 11 (45.8%) 1 (4.2%)
4 × 25 MBq day of surgery 0 (0%) 7 (29.2%)
4 × 25 MBq day before surgery 0 (0%) 7 (29.2%)
Result of SLN identification
Number of groins with at least 1 SLN identified 37 35
Number of groins with failed SLN identification1 1 1
Outcome specified per patient
Lateral tumor with unilateral SLN 10 (41.7%) 12 (50.0%) 0.745
Lateral tumor with bilateral SLN 5 (20.8%) 6 (25.0%)
Midline tumor with unilateral SLN 1 (4.2%) 1 (4.2%)
Midline tumor with bilateral SLN 8 (33.3%) 5 (20.8%)
Total number of SLNs identified 52 41
Mean number of SLNs identified per groin (range) 1.4 (1–3) 1.1 (1–2) 0.094
ICG; indocyanine green, MBq; megabequerel, SLN(s); sentinel lymph node(s).
1 Midline tumor with failed identification of bilateral SLNs.
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on lymphoscintigraphy were resected during surgery. In the fluores-
cence imaging group, 40 of the 41 (97.5%) SLNs identified on
lymphoscintigraphy were resected during surgery (p = 0.099). Signifi-
cant more additional SLNs were removed in the fluorescence imaging
group compared to the standard group, 13 (24.5%) versus 3 (6.1%)
(p = 0.011). The detection of significant more additional SLNs (8/19
vs 5/53 groins, p= 0.003, Table S1) was related to a higher injected ra-
dioactivity dose of ICG-99mTc-nanocolloid of 100MBq. No significant re-
lationship was found between the number of additional SLNs and time
interval between the injection and surgery (p = 0.937, Table S1).
In the standard group, 32 out of 49 (65.3%) resected SLNs coloured
blue, compared to 49 out of 53 (92.5%) fluorescent SLNs in the fluores-
cence imaging group (p< 0.001, Table 3). In the standard group in four
groins of three patients, only one blue, but not radioactive, SLN was de-
tected. Thesewere considered successful SLN procedures. In thefluores-
cence imaging group, 49 out of 53 SLNs were both radioactive and
fluorescent and 4 SLNs only radioactive.
A successful SLN procedure was achieved in 35/38 (92.1%) of the
groins in the standard group and in 35/36 (97.2%) of the groins in the
fluorescence imaging group (p = 0.331, Table 3). In the standard
group, four IFLs were performed: one because of failed SLN detection
on lymphoscintigraphy, one protocol deviation in an otherwise success-
ful SLN procedure, and two conversions to an IFL, because no SLN was
detected during surgery. In the fluorescence imaging group, one IFL
was performed because of failed SLN detection on lymphoscintigraphy.
In the standard group a complete SLN procedure was achieved in 31
of the 37 (83.8%) of the groins, compared to 34 of the 35 (97.1%) groins
in the fluorescence imaging group (p=0.056) (Table 3). In six groins in
the standard group and in one groin in the fluorescence imaging group,
not all SLNs that were identified by lymphoscintigraphy, were detected
during surgery. No significant relationship was found between either a
successful or complete SLN procedure and either the radioactivity
dose of (ICG)-99mTc-nanocolloid or time interval between injection
and surgery (Table S1).
3.4. Surgical and pathological outcomes
In four groins (11.4%) percutaneous fluorescence imaging of a lym-
phatic channel or SLN was seen, this was not seen in the standard
group with blue dye (p = 0.051) (Table 4). Fig. 2 shows an example
of the percutaneous visualization of a lymphatic channel by fluores-
cence imaging and was used to determine the location of the incision.676No intraoperative complications occurred. No significant differences
were found regarding: the amount of intraoperative blood loss (p =
0.403), mean length of incision (p = 0.140), and surgical resection
times in case of successful SLN procedure, including the removal of ad-
ditional SLNs (p = 0.126), or resection time of (un)successful SLN pro-
cedure including IFL (p = 0.911). In the standard group, pathological
examination showed eight metastases in seven (18.9%) of the 37 groins
(Table 4). This included onemetastasis in an additional SLN (radioactive
and blue). In the fluorescence imaging group, seven metastases were
found in five (14.3%) of the 35 groins. These included two metastases
in the additional resected SLNs (one SLN both radioactive and fluores-
cent, and one SLN only radioactive). In the subsequent IFLs, no other
positive LNswere found in neither patient group. Local vulvar resections
were not radical (R1 resection) in three (13.0%) patients in the standard
group versus two (8.7%) patients in the fluorescence group (p=0.636).
3.5. Short-term and long-term morbidity
In none of the 48 patients, adverse effects occurred that could be re-
lated to the use of blue dye or ICG-99mTc-nanocolloid. The mean follow-
up duration was 15 months (range 2–36) in the standard group and
14months (range 4–35) in thefluorescence imaging group (p=0.535).
In the standard group, six (25%) short-term complications occurred
in six patients: three groin infections, two wound breakdown, and one
lymphocyst formation (Table 4). Four of these complications (16.7%)
were seen after a SLN procedure only. In the fluorescence imaging
group one patient (4.2%) developed an infection of the groin after the
SLN procedure (p = 0.041, Table 4).
For analyses of long-term postoperative complications, we excluded
nine women who received additional surgery or radiotherapy to the
groins, leaving 19/24 patients in the standard group and 20/24 patients
of the fluorescence imaging group for analysis. One patient in the
standard group, in whom the SLN procedure was converted to an IFL,
developed recurrent cellulitis. In the fluorescence imaging group one
patient (5.0%) suffered from lymphedema after SLN procedure only
(p = 0.942).
4. Discussion
To our knowledge, this is the first randomized controlled trial re-
garding the detection of SLNs by NIR fluorescence imaging (using
ICG-99mTc-nanocolloid) compared to the standard SLN procedure
(using 99mTc-nanocolloid and blue dye) in patients with VSCC. We
Table 3
Intraoperative detection of sentinel lymph nodes.
Characteristics, n (%) 99mTc-nanocolloid + blue dye ICG-99mTc-nanocolloid P-value
Number of groins with attempted SLN procedure1 38 36
Number of groins with identified SLN on lymphoscintigraphy 37 35
Total number of resected SLNs during surgery 49 53
Mean number of SLNs resected per groin (range) 1.3 (0–4) 1.5 (1–5) 0.395
Number of resected SLNs by number of SLNs identified on lymphoscintigraphy2 46/52 (88.5%) 40/41 (97.5%) 0.099
Number of additional detected SLNs3 3/49 (6.1%) 13/53 (24.5%) 0.011
Proportion of resected SLNs detected by blue dye or fluorescence 32/49 (65.3%) 49/53 (92.5%) < 0.001
Method of SLN detection
Radioactive and blue or fluorescent 28/49 (57.1%) 49/53 (92.5%)
Radioactive only 17/49 (34.7%) 4/53 (7.5%)
Blue or fluorescent only 4/49 (8.2%) 0/53 (0%)
Number of groins with successful SLN procedure4 35/38 (92.1%) 35/36 (97.2%) 0.331
Groins with failed SLN detection on lymphoscintigraphy 1 1
Groins with failed SLN detecton during surgery 2 0
Number of groins with complete SLN procedure5 31/37 (83.8%) 34/35 (97.1%) 0.056
ICG; indocyanine green, SLN(s); sentinel lymph node(s).
1 Number of groins with identified SLN on lymphoscintigraphy, including groins with failed SLN identification on lymphoscintigraphy.
2 Number of SLNs that were identified on lymphoscintigraphy and also detected by surgery in the respective groin.
3 Extra resected SLNs, beside the resection of all SLNs that were identified on lymphoscintigraphy in the respective groin.
4 The number of groins with a successful SLN procedure, divided by the number of groins with attempted SLN procedure.
5 The intraoperative detection and removal of all SLNs identified on lymphoscintigraphy, and confirmed as lymphoid tissue by histopathology.
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ICG-99mTc-nanocolloid was superior to the standard SLN procedure
with blue dye, as significantly more resected SLNs were fluorescent
(92.5%) than blue (65.3%). This finding ensures easier intraoperative vi-
sual detection of SLNs guided by radio-guidance and fluorescence
imaging.
A successful SLN procedure was achieved in respectively, 92.1% and
97.2% of the groins in the standard andfluorescence imaging group. This
differencewas however, not significant. A trend to amore complete SLN
procedure, the opportunity of percutaneous visualization of a lymphatic
channel or SLN, and the resection of significantly more additional SLNs
was noted in the fluorescence imaging group. No significant differencesTable 4
Surgical and pathological outcomes and postoperative morbidity.
Outcome
Total number of resected SLNs during surgery
Pathology
Lymph node (no tumor)
Micrometastasis (≤ 2 mm)
Macrometastasis (> 2 mm)
Macrometastasis (> 2 mm) with capsular invasion
Resection margin vulvar tumour1
R0 resection
R1 resection
Percutaneous visual detection of lymphatic vessel or SLN
Intraoperative blood loss in ml
Intraoperative complications
Mean length of incision in mm (± SD)
Mean surgical time of successful SLN procedures in min2 (± SD)
Mean surgical time of successful or failed SLN procedures in min3 (± SD)
Mean follow-up in months (range)
Short-term morbidity
Complications after SLN procedure only
Complications after IFL, with or without previous SLN procedure
Long-term morbidity4
SLN(s); sentinel lymph node(s), N/A; not applicable, SD; standard deviation, IFL; inguinofemo
1 In both groups in one patient, no re-excison of the vulva was performed because of a previou
2 The time interval between skin incision and resection time of all SLNs (i.e. one or more SLNs
3 The time interval between skin incision and completion of successful SLN procedure or full IF
4 For long-term postoperative complications analysis, we excluded 9 women who received ad
677were noted between both groups regarding the length of the incision,
surgical time of the SLN procedures, intraoperative or postoperative
long-term complications. Although, significant more short-term post-
operative complications were documented in the standard group.
A successful SLN procedure per groin as found in our study of 92.1%
with the combined use of 99mTc-nanocolloid and blue dye, and a per-
centage of 65.3% blue SLNs, is comparable to the literature [4,6]. In the
standard group, four (8.2%) solely blue, non-radioactive, SLNs were de-
tected. This demonstrates the additional value of the intraoperative vi-
sualization of SLNs, as these procedures were regarded as successful
and a full IFL could be omitted. A successful SLN identification using
fluorescence imaging with ICG-99mTc-nanocolloid has been reported99mTc-nanocolloid + blue dye ICG-99mTc-nanocolloid P-value
49 53
N/A
41 (83.7%) 46 (86.8%)
5 (10.2%) 2 (3.8%)
3 (6.1%) 2 (3.8%)
0 (0%) 3 (5.6%)
23 23 0.636
20 (87.0%) 21 (91.3%)
3 (13.0%) 2 (8.7%)
0/37 (0%) 4/35 (11.4%) 0.051
67.5 (± 56.5) 89.5 (± 95.5) 0.403
0 (0%) 0 (0%) 1.000
59.1 ± 22.4 52.4 ± 14.1 0.140
16.7 (± 13.4) 22.2 (± 15.5) 0.126
23.8 (± 25.6) 23.2 (± 16.6) 0.911
15 (2–36) 14 (4–35) 0.535
6/24 (25.0%) 1/24 (4.8%) 0.041
4/17 1/22 0.079
2/7 0/2 0.391
1/19 (5.3%) 1/20 (5.0%) 0.942
ral lymphadenectomy.
s R0 resection at the time of SLN procedure.
, including additional SLNs).
L.
ditional surgery or radiotherapy to the groins.
Fig. 2. Example of the intraoperative detection of a sentinel lymph node by fluorescence imaging after the injection of ICG-99mTc-nanocolloid in a patient with VSCC. Percutaneous
visualization of fluorescence medial of the placed cross (A), on which the incision was adjusted. Intraoperative visualization of a lymphatic channel by fluorescence imaging (B),
leading to a deeper located fluorescent sentinel lymph node (C). Images in colour (left), green fluorescence overlay (center), and near-infrared fluorescence signal (right). Images
acquired by the Quest Spectrum Imaging System in real-time.
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and neck, penile, melanoma and vulva) [11,14,17]. Several studies have
been published concerning NIR fluorescence imaging using ICG or hy-
brid ICG-99mTc-nanocolloid to detect SLNs in patients with VSCC
[12–16,19,20,23–26]. Most studies were feasibility studies or assessed
the effect of different doses of ICG [13], optimal tracer formulation of
ICG-99mTc-nanocolloid [16,19], or explored the possibility of robot-
assisted SLN procedure using ICG [23,26]. KleinJan et al. [14] used the
same hybrid tracer and found that 96% of the SLNs were detected by
fluorescence imaging in a series of 21 patients with vulvar cancer. Our
resultswere comparable as 92.5% of the resected SLNs, including the ad-
ditional SLNs, were fluorescent. In addition, we found in 35 of the 36
groins (97.2%) at least one radioactive and fluorescent SLN.
The variations in the injected radioactivity dose of (ICG)-99mTc-
nanocolloid and time interval between injection and surgery in our
study were all within the recommended standard procedure [1,2]. It
may be hypothesized that the higher injected dose of 100 MBq in the
fluorescence imaging group, could contribute to the trend ofmore com-
plete SLN procedures in the fluorescence imaging group. However, we
found no significant relationship between the radioactivity dose of
ICG-99mTc-nanocolloid and either a successful or complete SLN proce-
dure, but this may also be because the study was not powered for this
comparison. On the other hand, a significant relationship was found be-
tween a higher injected dose ICG-99mTc-nanocolloid and the detection
of more additional SLNs (24.5%) in the fluorescence imaging group. A
percentage up to 24% additional SLNs has been reported previously
and corroborates our finding of the synergy using ICG-99mTc-
nanocolloid [14]. Furthermore, it is also possible that these additional
SLNs were part of a cluster on lymphoscintigraphy or were second-
tier nodes. The additional resected SLNs included also nodes with met-
astatic disease. The resection of additional, metastatic SLNs could678possibly improve the local control in groins as no other positive LNs
were found in the subsequent IFLs. However, it is not evident that the
resection of additional SLNs is associated with better outcome and it
possibly increases the risk of complications such as lymphedema. It
may be hypothesized, that a complete SLN procedure (i.e. not leaving
a SLN behind which was identified on the lymphoscintigraphy), could
contribute to a smaller risk of a false-negative SLN procedure. However,
we could not determine the false-negative rate of the performed SLNs
procedures, because of a relative short follow-up period and no stan-
dard IFL.
In the standard and fluorescence imaging group, in respectively
20.8% and 25.0% of the patients with a lateral tumor, bilateral SLNs
were identified on lymphoscintigraphy, which confirms previous find-
ings in literature [27]. Furthermore, failure of bilateral SLN identification
on lymphoscintigraphy in case of a midline tumor, has been reported in
up to 30% of the cases [27]. In our study this was found in only 4.2% of
the cases, one patient in each group.
We documented significant more short-term postoperative compli-
cations (25%) in the standard group. Wound breakdown was docu-
mented in 8.3% and groin infections in 12.5% of the patients in the
standard group. Reported complication rates after a SLN procedure in
literature [2,4] are 11.7% for wound breakdown and 4.5% for groin infec-
tions. This higher rate of groin infections in our study in the standard
group could be a result of the extended surgical procedure, as two of
the three groins infections occurred after an IFL. However, because
more IFLs were performed in the standard group and the total number
of patients was limited, no strong conclusions can be drawn about the
complication rate.
As NIR fluorescence imaging with ICG-99mTc-nanocolloid
outperformed blue dye in terms of visual guidance during surgery and
ICG does not alter the surgical field by dark staining or tattooing the
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tracer design is to extend routine radio-guidancewith visual imaging by
fluorescence-guidance. Radioactive tracers still remain necessary to
identify contralateral SLNs on lymphoscintigraphy in case of a lateral
tumor, the intraoperative localization of the SLNs and detection of
deeper located SLN. However, fluorescence imaging facilitates the iden-
tification during surgery by direct visualization and hereby more exact
localization of the SLN. In addition, this may be extra beneficial for the
surgical learning curve of fellows in gynecologic oncology.
Nevertheless, several requirements should be considered before
successful implementation of fluorescence imaging into standard SLN
procedure seems possible. This includes accessibility of a fluorescence
camera system, training in NIR fluorescence imaging, and convenience
with this technique. The presence of the NIR fluorescence camera
above the surgical field may interfere with the free space of movement
for the surgeon. Getting acquainted with the NIR fluorescence camera
system and interpretation of the images, could further improve the
use of fluorescence imaging [20], and possibly resulting in a shorter du-
ration of the SLN procedure. On the other hand, clinical implementation
of the hybrid ICG-99mTc-nanocolloid into standard of care is possible
since it is based on two clinically approved components and because
of the low costs of ICG.
In conclusion, we showed that the visual intraoperative identi-
fication of SLNs in patients with VSCC using ICG-99mTc-nanocolloid
and fluorescence imaging was superior compared to standard blue
dye. A successful SLN procedure was achieved in 97.2% of the
groins in the fluorescence imaging group versus 92.1% of the
groins in the standard group, although this difference was not sig-
nificant. NIR fluorescence imaging using ICG-99mTc-nanocolloid
has the potential to become part of the standard SLN procedure
in patients with early-stage VSCC to facilitate the identification
of the SLN by direct visualization.
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